ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Senior Scientist, DMPK at Atavistik Bio - ApplyBlast

Senior Scientist, DMPK

Atavistik Bio

5 months ago

Remote

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Senior Scientist, DMPK at Atavistik Bio, responsible for designing, executing, and interpreting non-clinical DMPK data to support therapy development.

Responsibilities

Design, execute, review, and interpret non-clinical DMPK data
Provide scientific expertise and strategic planning for preclinical studies
Communicate scientific planning, progress, results, and challenges to R&D teams and external audiences
Propose ADME/PK, biodistribution, and PK-PD approaches for high-impact projects
Manage consultants and vendors for DMPK studies

Skills

Qualifications

PhD., Pharm. D. or equivalent training in pharmacokinetics, pharmaceutical sciences, or related disciplines.5+ years of experience in bio/pharmaceutical industry, combined with drug development.Excellent communication and collaborative skills to work on multiple project teams including chemists, biologists and platform scientists.Highly organized, self-motivated with a desire to succeed in a fast-paced organization.Solid understanding of drug metabolism, bioanalysis, pharmacokinetics, preclinical pharmacology, and PK/PD modeling.

About Atavistik Bio

atavistikbio.com

Headquarters

Cambridge, Massachusetts, United States

Company Size

11-50 employees

Founded

2021

View Profile

Atavistik Bio is a clinical-stage biotechnology company focused on harnessing the power of allostery to develop transformative medicines. The company's approach enables selective modulation of disease-causing proteins, with lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor being developed for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio aims to deliver best-in-class allosteric therapeutics to address serious unmet patient needs.